産婦人科領域におけるHBKの基礎的・臨床的検討

DOI

書誌事項

タイトル別名
  • FUNDAMENTAL AND CLINICAL STUDIES OF HBK IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

抄録

HBK, a new aminoglycoside, was studied fundamentally And clinically in the held of, obstetrics and gynecology.<BR>1) In the study of MICs of HBK, the peak of MIC for S. aureus (100-fold diluted inocula) was 0.39μg/ml, the peak of MICa for E. ioli and S. marcescens were 1.56μg/ml, the peak of MIC for K. pneumoniae was 0.78μg/ml, and the peak of MICa for P. mirabilis, P.vulgaris and P. aeruginosa were 3.13μ/ml. And the peak of MICs for these microbes were comparable to that of DKB.<BR>2) When mothers were injected with 50 mg of HBK intramuscular injection, the maximum level of HBK in the mother's serum was 9.6μg/ml 43 minutes after the injection, and the level in the umbilical cord serum reached a peak of 3.4μg/ml 1 hour 4 minutes after the injection, and the level in the amniotic fluid reached a peak of 0.8μg/ml 2 hours 5 minutes after the injection. The level of HBK in newborn and maternal milk was below the detectable limit in all cases.<BR>3) A total of 12 cases, including each one case of mammary abscess, . mastitis, endometritis, cellulitis, infection of pelvic dead space, pelvic peritonitis and pyelonephritis and 5 cases of acute cystitis, were injected with 50-100mg of HBK by intramuscular injection or intravenous drip twice a day for 2 to 15 consecutive days. The clinical effect was excellent in 5 cases, good in 3 cases, poor in 3 cases and unknown in 1 case. Side effect was not observed in all cases, wh, ile, clinical laboratory data found elevation of S-GOT, S-GPT, Al-P and γ-GTP in 1 case.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ